熱門資訊> 正文
尽管在强劲的27财年EBITDA增长指引下未能达到2014年底线，Tilray仍上涨
2026-07-29 06:42
- Tilray Brands (TLRY) is up ~3% in after-hours trading Tuesday after its FQ4 EPS results missed expectations as its full-year EBITDA guidance of $68M-$75M represents double-digit year-over-year growth.
- Though a miss, in FQ4, Non-GAAP EPS of $0.11 compares to $0.07 in the year-ago period.
- For FY26 (ended May 31), adjusted EBITDA was $61.1M. That compares to $55M in fiscal 2025.
- Revenue in Tilray's biggest segment, beverages, grew ~61% YoY to $105.6M. Cannabis revenue rose ~5% to $71.5M.
- Tilray ended the fiscal year with cash and cash equivalents of ~$226M compared to ~$221.7M at the end of FY25.
More on Tilray
- Tilray May Benefit From Rescheduling Of Cannabis In The US
- Tilray Looks Cheap On The Surface, But Shareholders Still Need Proof
- Tilray Earnings Preview: What to expect
- Tilray launches THC pouch-based product Zonna
- Seeking Alpha’s Quant Rating on Tilray
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
